meningococcal Group A, C, W135 and Y conjugate vaccine: clinical use

Prescribing considerations

• Confirm indication, exposure risk, previous meningococcal vaccines, and product-specific licensed age.
• Consider reduced immunogenicity in immunocompromised people.
• Terminal complement inhibitor recipients remain at increased risk despite vaccination.
• Assess intramuscular haematoma risk in thrombocytopenia, coagulation disorders, or anticoagulant use.

Contraindications and cautions

• Hypersensitivity to an active component, excipient, or CRM197 carrier protein.
• Life-threatening reaction after a previous vaccine containing similar components.
• Postpone during acute severe febrile illness; minor infection alone is not a contraindication.

Monitoring

• Observe for immediate hypersensitivity and take precautions for vasovagal syncope.
• Check appearance and integrity before administration.
• Document suspected adverse reactions.

Clinical pharmacology

Capsular oligosaccharides from groups A, C, W135 and Y are conjugated to CRM197 carrier protein. Protection is inferred from serogroup-specific complement-mediated bactericidal antibodies.

Formulation and product differences

• Menveo solution for injection is ready to use and does not require reconstitution.
• Menveo powder and solution must be mixed correctly before administration.